NICE recommends 2 new breast cancer drugs
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
Page 29 of 39